WallStSmart
EOLS

Evolus Inc

NASDAQ: EOLS · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC

$5.18
-1.71% today

Updated 2026-04-29

Market cap
$344.82M
P/E ratio
P/S ratio
1.16x
EPS (TTM)
$-0.80
Dividend yield
52W range
$4 – $12
Volume
1.1M

Evolus Inc (EOLS) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item20152016201720182019202020212022202320242025
Revenue$0.00$0.00$0.00$0.00$34.92M$56.54M$99.67M$148.62M$202.09M$266.27M$297.18M
Revenue growth (YoY)+61.9%+76.3%+49.1%+36.0%+31.8%+11.6%
Cost of revenue$416000.00$326000.00$218000.00$0.00$8.01M$18.30M$43.53M$58.84M$61.56M$83.97M$104.41M
Gross profit$-416000.00$-326000.00$-218000.00$0.00$26.91M$38.24M$56.14M$89.77M$140.53M$182.30M$192.76M
Gross margin77.1%67.6%56.3%60.4%69.5%68.5%64.9%
R&D$20.68M$12.61M$6.69M$6.49M$3.97M$1.72M$2.06M$6.74M$15.43M$9.17M$9.58M
SG&A$9.88M$7.03M$4.82M$29.15M$29.15M$98.19M$118.36M$130.20M$157.45M$189.33M$220.79M
Operating income$-30.98M$-19.97M$-11.73M$-46.14M$-98.95M$-153.07M$-44.41M$-65.33M$-49.23M$-34.41M$-37.60M
Operating margin-283.3%-270.7%-44.6%-44.0%-24.4%-12.9%-12.7%
EBITDA$-30.56M$-19.64M$-11.51M$-45.93M$-92.10M$-144.75M$-39.06M$-53.85M$-41.81M$-25.00M$-28.86M
EBITDA margin-263.7%-256.0%-39.2%-36.2%-20.7%-9.4%-9.7%
EBIT$-30.98M$-19.97M$-11.73M$-45.94M$-97.11M$-152.43M$-45.37M$-57.58M$-47.68M$-31.02M$-37.60M
Interest expense$0.00$0.00$0.00$863000.00$7.95M$10.50M$1.40M$9.10M$13.83M$18.73M$19.69M
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-31.11M$-20.07M$-4.48M$-46.87M$-90.03M$-163.01M$-46.81M$-74.41M$-61.69M$-50.42M$-51.64M
Net income growth (YoY)+35.5%+77.7%-946.1%-92.1%-81.1%+71.3%-59.0%+17.1%+18.3%-2.4%
Profit margin-257.8%-288.3%-47.0%-50.1%-30.5%-18.9%-17.4%